＜＜Back

Next＞＞

Vol. 37　Suppl.1　2009

Opening Remarks

M. Hirano

Jpn Pharmacol Ther 2009　37(s1) s3

---

1．Functional characterization and species difference of organic anion transporting polypeptide for the hepatic uptake of organic anions in monkeys and dogs

Y. Debori, et al．

Jpn Pharmacol Ther 2009　37(s1) s9-13

---

2．Pharmacophore analysis and 3-dimensional quantitative structure activity relationships（3D-QSAR）of organic anion transporting polypeptide 1B1（OATP1B1）and organic anion transporting polypeptide 1B3（OATP1B3）substrates

E. Watanabe, et al．

Jpn Pharmacol Ther 2009　37(s1) s15-9

---

3．Search for transporters involved in the sinusoidal efflux of reduced glutathione（GSH）fromliver to blood

K. Maeda, et al．

Jpn Pharmacol Ther 2009　37(s1) s21-7

---

【Discussion 1～3】

Jpn Pharmacol Ther 2009　37(s1) s29-31

---

4．Adaptor protein complex 2（AP2）regulates the internalization of bile salt export pump（BSEP/ABCB11）from the cell-surface

K. Inamura, et al．　

Jpn Pharmacol Ther 2009　37(s1)s33-4

---

5．Effect of 4-phenylbutyrate on bile excretion of taurocholic acidthat decreases by LPS

S. Negoro, et al．

Jpn Pharmacol Ther 2009　37(s1) s35-6

---

6．Investigation of canalicular efflux mechanisms of SC-62807, a major metabolite of celecoxib

Chunyong Wu, et al．

Jpn Pharmacol Ther 2009　37(s1) s37-42

---

7．Investigation of the role of multidrug and toxin extrusion 1 in the biliaryexcretion of organic cation

S. Ito, et al

Jpn Pharmacol Ther 2009　37(s1) s43-7

---

【Discussion 4～7】

Jpn Pharmacol Ther 2009　37(s1) s49-51

---

8．Evaluation of the contribution of the hepatic efflux transporters on the biliary excretion of drugs using sandwich-cultured rat hepatocytes

K. Yoshida, et al．

Jpn Pharmacol Ther 2009　37(s1) s53-8

---

9．Epigenetic analysis of liver-specific transporters

S. Imai, et al．

Jpn Pharmacol Ther 2009　37(s1) s59-63

---

10．Positron emission tomography（PET）study for the evaluation of in vivo hepatobiliary transport using 15R-[¹¹C] TIC-Me

T. Takashima, et al

Jpn Pharmacol Ther 2009　37(s1) s65-9

---

11．Identification of transporters involved in the hepatobiliary transportof PET probe, 15R-[¹¹C] TIC, change in its plasma and hepatic concentration by drug interaction in humans and its prediction from in vitro experiments

Y. Sugiyama, et al．

Jpn Pharmacol Ther 2009　37(s1) s71-8

---

【Discussion 8～11】

Jpn Pharmacol Ther 2009　37(s1) s79-82

---

12．Investigation of the relationship between drug-induced hepatotoxicity and genotypes of glutathione S-transferases

R. Okada. et al．

Jpn Pharmacol Ther 2009　37(s1) s83-7

---

13．Interleukin-10 polymorphisms and the progression of liver fibrosis

C. Ishida, et al．

Jpn Pharmacol Ther 2009　37(s1) s89-92

---

15．An imbalance in plasma amino acids suppress the maturation of myeloiddendritic cells in advanced cirrhotic patients

E. Kakazu, et al．

Jpn Pharmacol Ther 2009　37(s1) s93-6

---

【Discussion 12～15】

Jpn Pharmacol Ther 2009　37(s1) s97-8

---

The tumor suppressor protein PTEN inhibits rat hepatics stellate cell activation

M. Takashima, et al.

Jpn Pharmacol Ther 2009　37(s1) s99-101

---

17．The role of chelatable iron on hepatic trans-free fatty acid-induced lipid accumulation and oxidative stress-related necrosis in isolated mice hepatocytes

K. Kon, et al．

Jpn Pharmacol Ther 2009　37(s1) s103-5

---

19．Impact of insulin resistance on the progression of chronic liver diseases

K. Kaji, et al．

Jpn Pharmacol Ther 2009　37(s1) s107-12

---

【Discussion 16～19】

Jpn Pharmacol Ther 2009　37(s1) s113-6

---

20．The histological course of nonalcoholic steatohepatitis
―A longitudinal study of repeat biopsies―

Y. Sumida, et al．

Jpn Pharmacol Ther 2009　37(s1) s117-22

---

21．Serum levels of advanced glycation endproducts（AGEs）and soluble receptor for AGEs（sRAGE）are useful parameters in determining the histological outcome in patients with nonalcoholic steatohepatitis（NASH）

T. Ishitobi, et al．

Jpn Pharmacol Ther 2009　37(s1) s123-7

---

22．The relationship between the gene polymorphisms of cytokines and MMPs and HCV-related hepatocellular carcinoma

K. Okamoto, et al．

Jpn Pharmacol Ther 2009　37(s1) s129-36

---

【Discussion 20～22】

Jpn Pharmacol Ther 2009　37(s1) s137-8

---

23．Follow-up of patients with NASH by BMI, levovist contrast ultrasound, and nuclear medicine tests

C. Koreeda, et al．

Jpn Pharmacol Ther 2009　37(s1) s139-45

---

24．Skeletal muscle similarly to visceral adipose tissue is linked to the development of nonalcoholic fatty liver disease

Y. Kitajima, et al．

Jpn Pharmacol Ther 2009　37(s1) s147-9

---

25．Nonalcoholic steatohepatitis in non-B non-C hepatocellular carcinoma

N. Maeda, et al．

Jpn Pharmacol Ther 2009　37(s1) s151-4

---

【Discussion 23～25】

Jpn Pharmacol Ther 2009　37(s1) 155-7

---

Closing Remarks

H. Takikawa　

Jpn Pharmacol Ther 2009　37(s1) s159